Analyze REGN

Technically, Regeneron Pharmaceuticals, Inc. is in a downtrend (below most moving averages). The weighted indicators point to “Sell”. Analysts are pricing in avg target $833 (+27%), buy. High institutional ownership (92%) signals smart-money confidence. Market backdrop: Positive market (Risk-On) — S&P 500 above the 200-day SMA, 1-month return -1.7%; VIX 16.1 (normal). Recent news sentiment: Positive sentiment (3 positive / 0 negative). Bottom line: the picture is mixed — better to wait for a clearer signal before entering.